<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">WNT4 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>WNT4</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>WNT4</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=WNT4" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/colorectal-cancer" style="color:#ef9a9a">Colorectal Cancer</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/melanoma" style="color:#ef9a9a">Melanoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">29 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">WNT4 Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>WNT4</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>WNT4</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=WNT4" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/colorectal-cancer" style="color:#ef9a9a">Colorectal Cancer</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/melanoma" style="color:#ef9a9a">Melanoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">29 edges</a></td>
</tr>
</table>
WNT4 (Wnt Family Member 4) is a member of the Wnt family of secreted lipid-modified signaling proteins that play critical roles in development, tissue homeostasis, and disease processes. WNT4 activates both canonical (β-catenin-dependent) and non-canonical (β-catenin-independent) Wnt signaling pathways, influencing cell fate determination, proliferation, migration, and survival. In the nervous system, WNT4 is expressed in various brain regions and regulates neural stem cell maintenance, neuronal differentiation, synapse formation, and neuroprotection. The gene is located on chromosome 1p36.23 (NCBI Gene ID: 7498, OMIM: 603490, Ensembl: ENSG00000163359, UniProt: P56705) and encodes a secreted protein of 351 amino acids. WNT4 is essential for female reproductive tract development and kidney morphogenesis, and its dysregulation has been implicated in various cancers and neurodegenerative diseases. In the brain, WNT4 expression is found in the developing and adult nervous system, with particular emphasis on the [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), and [substantia nigra](/brain-regions/substantia-nigra). Given its roles in neuronal survival and synaptic function, WNT4 has attracted attention as a potential therapeutic target in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). [@clevers2006]
The WNT4 gene (Gene ID: 7498) is located on chromosome 1p36.23 at base positions 22,226,458 to 22,252,456 on the forward strand. The gene spans approximately 26 kb and consists of 4 exons that encode the 351-amino-acid secreted WNT4 protein. The genomic structure is relatively simple, with the coding sequence contained within the last three exons. The promoter region of WNT4 contains multiple regulatory elements that control its expression in different tissues and developmental stages. Transcription factors including TCF/LEF, which mediate canonical Wnt signaling itself, can regulate WNT4 expression, creating feedback loops in the pathway. Additionally, sex-determining region Y-box (SOX) transcription factors and other developmental regulators control WNT4 expression in specific contexts. The gene shows high conservation across mammalian species, with particular conservation in the functional domains of the protein, including the cysteine-rich domain responsible for receptor binding. Epigenetic regulation, including DNA methylation at the WNT4 promoter, contributes to tissue-specific expression patterns. The relatively simple genomic organization of WNT4, combined with its complex regulation, allows for precise control of WNT4 expression in different biological contexts. @logan2004]
In the brain, WNT4 shows a characteristic expression pattern that varies during development and in the adult. During embryonic development, WNT4 is expressed in the developing telencephalon, where it plays roles in cortical patterning and neural progenitor cell proliferation. In the adult brain, WNT4 expression is maintained in several regions, with highest expression in the hippocampus, particularly in the dentate gyrus and CA3 region, areas associated with neurogenesis and memory formation. The cerebral cortex also shows WNT4 expression, with particular emphasis in the superficial layers. In the midbrain, WNT4 is expressed in the substantia nigra, including both dopaminergic neurons and surrounding cells, suggesting potential relevance to Parkinson's disease. WNT4 is also expressed in the cerebellum, particularly during development. Within neural cells, WNT4 is expressed in neurons, astrocytes, and oligodendrocytes, though the specific expression patterns differ between cell types. Neural stem cells in the subventricular zone and subgranular zone of the dentate gyrus express WNT4, where it contributes to stem cell maintenance and neurogenesis. The expression of WNT4 in these regions, which are affected in neurodegenerative diseases, makes it a candidate for involvement in disease processes. @varelanallar2015]
WNT4 activates both canonical and non-canonical Wnt signaling pathways, providing diverse biological effects depending on cellular context. The canonical Wnt/β-catenin pathway involves WNT4 binding to Frizzled (FZD) receptors and low-density lipoprotein receptor-related protein (LRP) co-receptors, leading to inhibition of β-catenin degradation and its accumulation in the cytoplasm and nucleus. In the nucleus, β-catenin interacts with TCF/LEF transcription factors to regulate target gene expression. Canonical Wnt signaling controls cell proliferation, differentiation, and fate determination during development and in adult tissue homeostasis. The non-canonical Wnt pathways include the Wnt/planar cell polarity (PCP) pathway and the Wnt/calcium pathway. In the Wnt/PCP pathway, WNT4 binding to FZD receptors activates small GTPases including RAC1 and RHOA, leading to cytoskeletal reorganization and cell polarity. The Wnt/calcium pathway involves WNT4-induced release of intracellular calcium through FZD receptors coupled to G proteins, leading to activation of calcium-dependent enzymes including calcineurin and CaMKII. These non-canonical pathways are particularly important for morphogenesis and tissue patterning. WNT4 can signal through both pathways, and the relative activation depends on the receptor repertoire and cellular context. The dual signaling capacity of WNT4 contributes to its diverse biological functions in the nervous system. @van2020]
WNT4 signals through multiple receptors in the Frizzled family and may interact with other receptor types. The primary receptors for WNT4 are the Frizzled (FZD) receptors, a family of ten G protein-coupled receptors (FZD1-10) that serve as Wnt receptors. Different FZD receptors show distinct expression patterns and signaling properties, leading to different cellular responses to WNT4. In the brain, FZD1, FZD3, FZD5, and FZD9 are among the FZD receptors expressed, and WNT4 can interact with several of these. Additionally, WNT4 may signal through receptor tyrosine kinase-like orphan receptors (ROR1 and ROR2), which are alternative Wnt receptors that can mediate both canonical and non-canonical signaling. ROR2 is particularly important for non-canonical Wnt signaling. The LRP co-receptors (LRP5, LRP6) are required for canonical Wnt signaling through FZD receptors, as they serve as the platform for β-catenin destruction complex inhibition. The interaction between WNT4 and its receptors is mediated by the cysteine-rich domain (CRD) of FZD, which binds Wnt proteins with high affinity. The specificity of WNT4-receptor interactions determines the downstream signaling pathway activation and ultimately the cellular response. Understanding these interactions is important for developing therapeutic approaches that target WNT4 signaling. @schulte2019]
WNT4 and the broader Wnt signaling pathway have been increasingly implicated in Alzheimer's disease pathogenesis, with evidence suggesting both protective and pathological roles. The Wnt/β-catenin pathway is dysregulated in AD brains, with alterations in pathway components and target gene expression observed in human tissue and experimental models. Some studies suggest that Wnt signaling may be protective in AD, as activation of the pathway can reduce amyloid-β production and toxicity, promote neuronal survival, and support synaptic function. WNT4 itself has been shown to have neuroprotective effects in cellular models, potentially through both canonical and non-canonical pathways. However, other evidence suggests that excessive or dysregulated Wnt signaling may contribute to AD pathology. The relationship between Wnt signaling and the two major pathological hallmarks of AD—amyloid-β plaques and neurofibrillary tau tangles—appears complex, with bidirectional interactions. Amyloid-β can dysregulate Wnt signaling, and Wnt signaling can influence amyloid precursor protein (APP) processing and amyloid-β production. Similarly, Wnt signaling interacts with tau pathology, with both protective and potentially harmful effects reported. WNT4 expression is altered in AD brains, and this dysregulation could contribute to disease processes. The overall role of WNT4 in AD thus appears complex and may depend on specific disease stages and cellular contexts. The therapeutic targeting of Wnt signaling in AD has attracted interest, though the complexity of the pathway requires careful consideration of potential effects. @inestrosa2012]
WNT4 and Wnt signaling have also been implicated in Parkinson's disease, with relevance to both dopaminergic neuron development and disease processes. During development, Wnt signaling, including signaling through WNT4, is critical for the specification and differentiation of dopaminergic neurons in the midbrain. This developmental role has implications for understanding how dopaminergic neurons may be susceptible to degeneration in PD. In the adult substantia nigra, WNT4 continues to be expressed, and Wnt signaling contributes to the maintenance and survival of dopaminergic neurons. Studies in experimental models have shown that Wnt signaling can protect dopaminergic neurons from various insults relevant to PD pathogenesis, including oxidative stress, mitochondrial toxins, and neuroinflammation. This neuroprotective potential has made Wnt signaling an attractive target for PD therapeutics. However, as in AD, the role of Wnt signaling in PD is complex and not fully understood. Some studies have also suggested that altered Wnt signaling may be involved in the characteristic inclusion bodies (Lewy bodies) found in PD, though this remains an active area of investigation. WNT4 specifically may contribute to dopaminergic neuron survival and function, though more direct evidence is needed. The link between WNT4 and PD thus spans development, survival, and potential disease mechanisms, making it an area of significant interest. @inestrosa2015]
WNT4 exerts neuroprotective effects through multiple mechanisms that are relevant to neurodegenerative diseases. In neurons, WNT4 can activate pro-survival signaling pathways including PI3K/Akt and MAPK/ERK, which promote cell survival and protect against apoptotic cell death. WNT4 can also enhance mitochondrial function and protect against mitochondrial dysfunction, a central feature of many neurodegenerative conditions. The effects of WNT4 on oxidative stress are particularly relevant, as WNT4 signaling can upregulate antioxidant defenses and reduce oxidative damage. Additionally, WNT4 has anti-inflammatory effects, reducing the activation of microglia and the production of pro-inflammatory cytokines that contribute to neuroinflammation in neurodegenerative diseases. At the synapse, WNT4 promotes synaptic formation and function, potentially through effects on presynaptic differentiation and postsynaptic assembly. These synaptic effects could be relevant to the synaptic loss that occurs in AD and other neurodegenerative conditions. WNT4 also affects neurogenesis in the adult brain, potentially through effects on neural stem cells in the hippocampus and subventricular zone. The ability of WNT4 to act on multiple pathways and cell types provides broad neuroprotective potential, though this also creates complexity for therapeutic targeting. Understanding the specific mechanisms by which WNT4 provides neuroprotection in different disease contexts will be important for developing effective therapies. @wexler2009]
WNT4 plays important roles in synapse formation and plasticity, processes critical for learning, memory, and overall brain function. During synaptogenesis, WNT4 acts as a synaptogenic factor that promotes the formation of both excitatory and inhibitory synapses. At the presynaptic terminal, WNT4 signaling can induce presynaptic differentiation and enhance neurotransmitter release. At the postsynaptic density, WNT4 affects the recruitment and assembly of postsynaptic proteins, including neurotransmitter receptors and scaffolding molecules. These effects involve both canonical β-catenin signaling and non-canonical pathways. WNT4 also modulates synaptic plasticity, the activity-dependent changes in synaptic strength that underlie learning and memory. WNT4 can affect long-term potentiation (LTP) and long-term depression (LTD), forms of synaptic plasticity critical for memory formation. These effects involve modulation of NMDA receptor function, AMPA receptor trafficking, and intracellular signaling pathways. The role of WNT4 in synaptic plasticity is particularly relevant to neurodegenerative diseases, in which synaptic loss and dysfunction are key features that correlate with cognitive decline. The ability of WNT4 to modulate synapses suggests potential therapeutic approaches for addressing synaptic deficits in conditions like AD. @barros2019]
WNT4 signaling interacts with neuroinflammatory processes that are increasingly recognized as important contributors to neurodegenerative disease progression. Neuroinflammation, driven primarily by activated microglia, is a prominent feature of AD, PD, and other neurodegenerative conditions. WNT4 can modulate microglial activation and the inflammatory response. In some contexts, WNT4 has anti-inflammatory effects, reducing microglial activation and the production of pro-inflammatory cytokines. This anti-inflammatory effect could be protective in neurodegenerative diseases, as excessive neuroinflammation can cause secondary neuronal damage. However, the relationship between Wnt signaling and neuroinflammation is complex, as inflammatory signals can also modulate Wnt pathway activity. The crosstalk between Wnt signaling and inflammatory pathways creates a network of interactions that can influence disease progression in complex ways. Understanding how WNT4 specifically affects neuroinflammation in different disease contexts will be important for determining its overall role in neurodegeneration. @mandel2019]
Dysregulated WNT4 expression and function have been implicated in several types of cancer, reflecting the role of Wnt signaling in cell proliferation and survival. In gynecological cancers, including endometrial and ovarian cancers, WNT4 overexpression has been reported and associated with disease progression. In breast cancer, WNT4 has been implicated in tumor initiation, progression, and metastasis. The role of WNT4 in cancer appears to be context-dependent, with both tumor-promoting and tumor-suppressive effects reported in different cancer types. The canonical Wnt/β-catenin pathway is frequently activated in cancers through mutations in pathway components, and WNT4 can contribute to this activation. In some contexts, WNT4 may act as an oncogene, while in others it may have tumor-suppressive functions. The study of WNT4 in cancer has provided insights into Wnt signaling in general and has highlighted the complexity of this pathway in disease. The cancer-related findings may also inform understanding of WNT4 in other diseases, though the relationship between WNT4's roles in cancer and neurodegeneration remains to be fully clarified. @cerpa2015]
WNT4 has been implicated in neurodevelopmental and psychiatric disorders, conditions that involve alterations in brain development or function. In schizophrenia, Wnt signaling dysregulation has been reported, and WNT4 expression may be altered in this disorder. The role of WNT4 in synapse formation and plasticity, processes that are disturbed in schizophrenia, could be relevant to these findings. WNT4 has also been studied in the context of autism spectrum disorders, where Wnt signaling alterations have been implicated in the developmental defects that characterize this group of conditions. Additionally, WNT4 has been associated with mood disorders including depression and bipolar disorder, possibly through effects on neural circuits involved in mood regulation. The developmental functions of WNT4, including its role in neural stem cell maintenance and neuronal differentiation, may contribute to these associations. However, the specific roles of WNT4 in these conditions remain to be fully characterized, and more research is needed to establish causality and understand the mechanisms involved. @patel2022]
The neuroprotective and synaptic functions of WNT4 make it an attractive target for therapeutic intervention in neurodegenerative diseases. Several approaches to targeting WNT4 signaling are being explored, including direct administration of WNT4 protein, small molecule agonists of Wnt signaling, and gene therapy approaches. WNT4 protein delivery has shown promise in experimental models, with neuroprotective effects observed in models of AD and PD. However, the delivery of WNT4 to the brain presents challenges related to the blood-brain barrier and the need for sustained delivery. Small molecule Wnt pathway agonists are being developed and tested for neurodegenerative diseases, though the lack of specificity for WNT4 versus other Wnt ligands remains a concern. Gene therapy approaches using viral vectors to deliver WNT4 or activate Wnt signaling are also under investigation. Additionally, targeting the downstream effectors of WNT4 signaling may provide more specific effects. The development of biomarkers for WNT4 pathway activity could help identify patients who might benefit from Wnt-targeting therapies and monitor treatment responses. Despite the challenges, targeting WNT4 signaling remains an active area of investigation for neurodegenerative diseases. @silva2020]
Several challenges face the development of WNT4-based therapies for neurodegenerative diseases. The complexity of Wnt signaling, with multiple pathways and receptors, makes it difficult to achieve specific effects without causing unwanted side effects. The widespread expression of Wnt pathway components and the important functions of this pathway in many tissues raise concerns about potential off-target effects and toxicity. Additionally, the timing of intervention may be critical, as Wnt signaling may have different effects at different disease stages. Understanding the specific roles of WNT4 in different neurodegenerative diseases and in different cell types will be important for developing effective therapies. Better tools for studying WNT4, including selective agonists and antagonists, are needed to advance this research. The development of biomarkers that can indicate WNT4 pathway activity in patients will also be important. Finally, clinical trials will be needed to test the safety and efficacy of WNT4-targeting approaches in human patients. Despite these challenges, the neuroprotective functions of WNT4 make it a promising target for further investigation and potential therapeutic development. @onyike2019]
Current research on WNT4 in the nervous system spans multiple areas, from basic mechanism studies to translational investigations. At the basic level, researchers are working to understand the specific signaling pathways activated by WNT4 in different cell types, the receptors that mediate these effects, and the downstream effectors that translate WNT4 signals into cellular responses. At the cellular level, studies are examining WNT4's roles in neural stem cell biology, neuronal differentiation, synapse formation, and neuron survival. In vivo studies are investigating WNT4 function in the intact brain and its effects on behavior. Translational research is exploring WNT4 as a therapeutic target in models of AD, PD, and other neurodegenerative conditions. Additionally, studies are examining WNT4 in the context of neuroinflammation and the interaction between Wnt signaling and other pathways relevant to neurodegeneration. The development of new tools, including WNT4-selective agents and genetic models, is facilitating this research. The overall goal is to develop a comprehensive understanding of WNT4's roles in the nervous system and to translate this understanding into therapies for neurodegenerative diseases. @arrant2019]
Despite significant progress, many questions about WNT4 in the nervous system remain unanswered. The specific roles of WNT4 in different neuronal populations and brain regions need further clarification. The relative contributions of canonical versus non-canonical Wnt signaling to the neuroprotective effects of WNT4 are not fully understood. The relationship between WNT4 and specific disease processes in AD and PD requires more direct investigation, particularly using human tissue and relevant model systems. The optimal approach for targeting WNT4 therapeutically, including timing, delivery method, and specific molecular target, remains to be determined. The potential for WNT4-based therapies to cause adverse effects, given the important functions of Wnt signaling in other tissues, needs to be addressed. Additionally, the interactions between WNT4 and other Wnt ligands, and between Wnt signaling and other pathways involved in neurodegeneration, require further investigation. Answering these questions will require continued multidisciplinary research combining molecular biology, cellular physiology, animal models, and clinical investigation. The investigation of WNT4 thus offers significant opportunities for advancing understanding of brain function and developing new therapies for neurodegenerative diseases.
The following diagram shows the key molecular relationships involving WNT4 Gene discovered through SciDEX knowledge graph analysis: